SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Eli Lilly & Company (LLY)

LLY RSS Feed
Add LLY Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/25/2017 1:45:56 PM - Followers: 12 - Board type: Free - Posts Today: 0

Headquarters Lilly Corporate Center Indianapolis, IN 46285 Contact Phone: 317-276-2000 Fax: 317-276-4878 Web site http://www.lilly.com Basics Sector: Healthcare Industry: Drug Manufacturers - Major Full Time Employees: 40,600 Background Eli Lilly and Company engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. It offers neuroscience products, including Zyprexa for the treatment of schizophrenia, bipolar mania, and bipolar maintenance; Cymbalta for depression and diabetic peripheral neuropathic pain; Strattera for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and adults; Prozac for depression, bulimia, and obsessive-compulsive disorders; and Symbyax for bipolar depression. The company also provides endocrinology products that comprise Humalog, Humalog Mix 75/25, Humalog Mix 50/50, and Humulin for the treatment of diabetes; Actos and Byetta for type 2 diabetes; Evista for the prevention and treatment of osteoporosis in post-menopausal women; and Forteo for the treatment of severe osteoporosis in women and men. Its oncology products include Gemzar for the treatment of pancreatic cancer, and Alimta for malignant pleural mesothelioma and non-small cell lung cancer; and cardiovascular products comprise Cialis for the treatment of erectile dysfunction, ReoPro for use as an adjunct to percutaneous coronary intervention, and Xigris for the treatment of adults with severe sepsis at high risk of death. In addition, the company offers animal health products, including Rumensin, a cattle feed additive; Coban, Monteban, and Maxiban for use in poultry; Surmax for swine and poultry; and Elector, a parasiticide for use on cattle and premises, as well as other pharmaceutical products, such as Vancocin HCl to treat staphylococcal infections, and Ceclor for the treatment of bacterial infections. Eli Lilly serves hospitals, pharmacies, physicians, and other health care professionals. It has a strategic alliance with MacroGenics, Inc.; a licensing and development agreement with BioMS Medical Corp.; and an agreement with Glenmark Pharmaceuticals Limited India. The company was founded in 1876 and is based in Indianapolis, Indiana. Officers Mr. Sidney Taurel, 59 Exec. Chairman and Chief Exec. Officer Dr. John C. Lechleiter Ph.D., 54 Pres, Chief Operating Officer, Exec. Director, Chairman of Operations Committee, Member of Science & Technology Committee and Member of Policy & Strategy Committee Mr. Derica W. Rice, 43 Chief Financial Officer, Sr. VP, Member of Operations Committee and Member of Policy & Strategy Committee Dr. Steven M. Paul M.D., 57 Exec. VP of Science & Technology, Pres of Lilly Research Laboratories, Member of Operations Committee and Member of Policy & Strategy Committee Mr. Robert A. Armitage, 59 Sr. VP, Gen. Counsel and Member of Policy & Strategy Committee Fundamentals Profit Margin: 15.85% Operating Margin: 25.78% Return on Assets: 12.32% Return on Equity: 23.96% Revenue: 18.63B Gross Profit: 14.38B EBITDA: 5.85B Net Income Avl to Common: 2.95B Diluted EPS: 2.71 Qtrly Earnings Growth (yoy): 545.80% Total Cash: 4.83B Total Debt: 5.01B Book Value Per Share: 12.046 Operating Cash Flow: 5.15B Levered Free Cash Flow: 1.19B Ownership Shares Outstanding: 1.14B Float: 997.16M % Held by Insiders: 12.25% % Held by Institutions: 64.20% Patent expiration 10 Pharmaceutical Stocks and Their Patent Expiration Drugs by: Stockerblog posted on: April 07, 2008 The next two to four years are an important time frame for many pharmaceutical companies. This is when many of the top selling drugs go off patent. Here is a list of the large pharmas with some of their top selling drugs that are set to 'expire.' AstraZeneca plc (AZN) has the cholesterol drug Crestor, which is set to go off patent in the year 2012. This was recently ranked the 42nd best selling drug. It also has the asthma drug, Symbicort, which expires the same year. Seroquel, an antipsychotic used to treat schizophrenia and the 16th best selling drug, expires 2011. The stock has a P/E of 11, a PEG of 2.77, and pays a yield of 4.6%. Eli Lilly & Co. (LLY) has the eighth best selling drug, Zyprexa, which is used to treat schizophrenia, and has a patent expiration of 2011. It also has Actos for Type 2 diabetes which goes off patent the same year. Lilly has a P/E of 19, a PEG of 1.81, and a yield of 3.6%. Forest Laboratories Inc. (FRX) has the drug Lexapro, also known as Cipralex which expires in 2012. The drug is an antidepressant used to treat depression and anxiety disorders. The stock has a PE of 23, and a PEG of 1.1. Glaxosmithkline plc (GSK) has the asthma drug Advair, also known as Seretide which expires in 2010, and the diabetes drug Avandia expiring 2012. The stock has a PE of 12, a PEG of 4.21, and a yield of 5.6%. Johnson & Johnson's (JNJ) antibiotic drug, Levaquin, goes off patent in 2010. The stock has a PE of 18, a PEG of 1.99, and a yield of 2.5%. Merck & Co. Inc. (MRK) has the asthma drug Singulair which expires in 2012, and Cozaar for hypertension which expires in 2010. The stock has a P/E of 27, a PEG of 1.21, and a yield of 4%. Novartis AG (NVS) has the Zometa cancer drug and the Diovan hypertension drug, both expiring 2012. The stock has a P/E of 10, a PEG of 1.22, and a yield of 2.9%. Pfizer Inc. (PFE) has Lipitor for cholesterol, estimated to expire 2010, Aricept for Alzheimer’s, expiring 2010, and Xalatan for glaucoma, which goes off patent in 2011. The stock has a P/E of 18, a PEG of 2.03, and has a 6% yield. Both Sanofi-Aventis (SNY) and Bristol-Myers Squibb Co. (BMY) have Aprovel for high blood pressure expiring 2011, and the anticoagulant Plavix, expiring the same year. Recent developments Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement Wednesday April 2, 12:00 pm ET INDIANAPOLIS, April 2, 2008 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) has adjusted the time of its conference call for its first quarter 2008 financial results announcement. The company will still announce its financial results for the first quarter of 2008 on Monday, April 21, 2008. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will now be held from 8:00 a.m. to 9:00 a.m. EDT. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at www.lilly.com. The webcast of the conference call will be available for replay through May 23, 2008. Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) Source: Eli Lilly and Company Share price
LLY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
LLY News: Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine 08/04/2017 06:45:00 AM
LLY News: Statement of Changes in Beneficial Ownership (4) 08/01/2017 10:56:49 AM
LLY News: Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important ... 07/31/2017 09:00:00 AM
LLY News: Quarterly Report (10-q) 07/28/2017 11:45:00 AM
LLY News: Lilly Reports Second-Quarter Results 07/25/2017 07:00:00 AM
PostSubject
#87   $LLY Dave Ricks, Lilly's CEO reiterates 5% revenue NorFoster 07/25/17 01:45:56 PM
#86   $LLY Dave Ricks, Lilly's CEO reiterates 5% revenue NorFoster 07/25/17 01:41:36 PM
#85   Jardiance does have not the amputation side effect DewDiligence 06/21/17 07:34:07 PM
#84   If Lilly doesn't sign with Anavex soon, they Whiskey/Sausage 12/11/16 02:58:58 PM
#83   AstraZeneca Cuts Jobs, Signs New Collaboration With Eli trendmkr 12/09/16 11:11:07 AM
#82   Will LLY buy AVXL after seeing their Alzheimers biotechnician 12/08/16 10:06:15 AM
#81   FWIW, Merrill has removed LLY from its US ilpapa 11/28/16 02:18:15 PM
#80   See AVXL work: biotechnician 11/28/16 10:36:12 AM
#79   I thought this was an LLY board...lol! ExtremelyBullishZig 11/26/16 09:01:25 AM
#78   LLY bearish 67.29 stocktrademan 11/23/16 11:25:25 AM
#77   Will LLY buy AVXL or will it be biotechnician 11/23/16 08:23:06 AM
#76   Anavex has a drug that does slow the plexrec 11/23/16 08:14:01 AM
#75   LLY bullish 79.06 stocktrademan 08/19/16 04:24:03 PM
#74   http://www.fiercebiotech.com/story/can-eli-lillys-regulatory-gambit-salvage-its- Cbdpotential 03/22/16 01:50:14 PM
#73   Here’s a Look at the Current CDK Inhibition Landscape nyctraydr 02/12/16 11:34:52 AM
#72   Eli Lilly Reports EPS and Revenues In-Line, Reaffirms nyctraydr 01/29/16 10:56:37 AM
#71   FDA approval !! stock1ace1 12/16/15 11:22:38 PM
#70   Article discusses Eli Lilly: What are the Implications venturecapp 12/01/15 03:23:34 PM
#69   Payers push back on LLY’s Jardiance: #msg-117435122. DewDiligence 10/02/15 03:45:44 PM
#68   * * $LLY Video Chart 06-11-15 * * ClayTrader 06/11/15 05:15:22 PM
#67   LLY buys North American rights to Erbitux from DewDiligence 04/17/15 11:05:00 AM
#66   LLY issues 2015 non-GAAP EPS guidance: #msg-109697754. DewDiligence 01/07/15 12:45:05 PM
#65   quick ques,what does everybody think lilly will be cajunmanbob 12/02/14 09:38:45 PM
#64   biotech_researcher Tuesday, 10/28/14 05:20:17 PM TREND1 11/05/14 07:26:03 PM
#63   LLY D TREND1 11/05/14 07:23:52 PM
#62   What is new in Bio Tech and where Setay 11/02/14 05:52:28 AM
#61   DewDiligence, Sorry for the delay in answering your stockplayer7 08/28/14 10:44:02 AM
#60   What does FS mean? DewDiligence 06/22/14 03:58:04 PM
#59   I'm in. 4 FS & a sweet divy. stockplayer7 06/12/14 11:19:28 AM
#57   "Looking at the universe of stocks we cover chmcnfunds 11/12/13 02:55:58 PM
#56   Eli Lilly Bulls: How Will 2014 Treat You? chmcnfunds 10/29/13 10:19:46 AM
#55   Eli Lilly: Cymbalta Patent Expiry Quantified chmcnfunds 10/28/13 02:01:25 PM
#54   Earnings Beat from Eli Lilly Again - Analyst Blog chmcnfunds 10/25/13 08:46:11 AM
#53   FDA Approves Addition to CIALIS® (tadalafil) Product Label chmcnfunds 10/25/13 08:30:30 AM
#52   Board of Directors authorized a new $5 billion ViralBond 10/23/13 02:17:54 PM
#51   Lilly diabetes drugs, price hikes fuel 6% sales boost chmcnfunds 10/23/13 01:43:24 PM
#50   FDA Grants Lilly's Ramucirumab Priority Review For Advanced chmcnfunds 10/23/13 07:28:37 AM
#49   Eli Lilly beats by $0.08, beats on revenues chmcnfunds 10/23/13 07:25:02 AM
#48   Eli Lilly & Co. : Lilly Declares Fourth-Quarter chmcnfunds 10/22/13 03:03:06 PM
#47   10 top drugs in biopharma's late-stage pipeline chmcnfunds 10/08/13 12:14:13 PM
#46   Earnings in detail ECole 07/24/13 11:09:32 AM
#45   I posted the CC highlights in #msg-89870017. DewDiligence 07/12/13 12:44:24 PM
#44   Business Update Call Updates ECole 07/12/13 10:40:01 AM
#43   6:20 AM Eli Lilly (LLY) declares $0.49/share quarterly johnsyn 05/07/13 08:26:44 AM
#42   The uptrend is continuing since March 2009 and investora2z 03/28/13 10:39:57 AM
#41   Good Story mentioning Eli Lilly... Emerging Growth 01/16/13 12:36:11 PM
#40   4:50 PM Eli Lilly & Co. (LLY) declares johnsyn 12/17/12 05:38:49 PM
#39   http://seekingalpha.com/article/1000731-5-stocks-that-stand-to-benefit-from-unme Thenextjamn 11/13/12 03:46:08 PM
#38   10:52 AM Leerink Swan ups Eli Lilly (LLY johnsyn 10/15/12 05:27:15 PM
#37   4:20 PM Eli Lilly (LLY) declares $0.49/share quarterly johnsyn 10/15/12 05:13:32 PM
PostSubject